SCHEMBL4911220

SCHEMBL4911220

O=Cc1c(Cl)nc(NC2CC2)nc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 3/20 0.39
CYP2C9 P11712 1/20 0.34
NPR3 P17342 1/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 2/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.32
CDC7 O00311 1/20 0.32
DAPK3 O43293 1/20 0.32
ROCK2 O75116 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
PRKACA P17612 1/20 0.32
CDK2 P24941 1/20 0.32
FLT3 P36888 1/20 0.32
CSNK1A1 P48729 1/20 0.32
CLK2 P49760 1/20 0.32
GSK3B P49841 1/20 0.32
CDK7 P50613 1/20 0.32
CDK9 P50750 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16058116 0.88 MAPK1 (0.49) PDE4AMAPK1CDC7DAPK3ROCK2
SCHEMBL4911643 0.77 PDE4A (0.36) PDE4ACYP2C9NPR3CYP2C19MAPK1
SCHEMBL29953279 0.73 PDE10A (0.54) PDE4APDE4BPDE4CPDE4D
SCHEMBL14220773 0.71 PDE4A (0.36) PDE4ACYP2C19LMNARECQL
SCHEMBL11474745 0.71 PDE4A (0.48) PDE4ACYP2C9NPR3CYP2C19MAPK1
SCHEMBL27806127 0.71 KCNH2 (0.38) CDK7CDK9
SCHEMBL1061432 0.71 CA1 (0.50) CYP2C9CYP2C19LMNASMN1; SMN2HTR2B
SCHEMBL10850056 0.71 PDE4A (0.40) PDE4ACYP2C9MAPK1
SCHEMBL5127390 0.70 PDE4A (0.60) PDE4ACYP2C9NPR3CYP2C19LMNA
SCHEMBL10168943 0.70 PDE4A (0.66) PDE4ACYP2C9NPR3CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF PDE4A 1/4885CYP2C9 1938/4885NPR3 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.